Xaracoll

Brand (proprietary) name

XARACOLL

Generic (nonproprietary) name

No authoritative public data was located for this field.

Active ingredient(s)

No authoritative public data was located for this field.

Strength(s)

No authoritative public data was located for this field.

Dosage form(s)

No authoritative public data was located for this field.

Route(s)

No authoritative public data was located for this field.

Manufacturer / labeler

INNOCOLL PHARMACEUTICALS

Product class

Brand (derived from FDA marketing category)

Marketing category

NDA

Application number(s)

NDA209511

Earliest marketing start

Aug 28, 2020

Products / packages indexed

1 / 2

Also searchable as: XARACOLL

Prescribing information on DailyMed (NLM)

• C9089CC-code: Hospital outpatient (OPPS) codesTerminated Dec 31, 2025Derived calculation

  Bupivacaine, collagen-matrix implant, 1 mg

  Derived: 2 of 2 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for C9089. CMS quarters Q1 2022 – Q4 2025Not in the latest CMS crosswalk.

  C-codes are temporary codes for hospital outpatient use under the Medicare Outpatient Prospective Payment System, including pass-through drugs and biologicals (many in C9xxx) and devices. They are generally not reported by physician offices; other payers may not recognize them.

No authoritative public data was located for this field.

Home infusion per diem (S-codes)

Medicare

Not payable by Medicare — CMS coverage code I (all 2 codes)

Part B pricing indicator

00 — Not separately priced by Part B (all 2 codes)

National payment amount

No authoritative public data was located for this field.

Which Medicare benefit pays for this drug?

• Self-administered drug (SAD) exclusion lists Drugs each MAC excludes from “incident to” Part B coverage because they are usually self-administered.
• Find your Medicare contractor (MAC) A/B and DME MAC jurisdictions by state — local coverage and prior-authorization rules come from your MAC.
• CMS discarded drug (JW/JZ) guidance

No current Medicare Billing and Coding article lists C9089.

• FDA NDC Directory data is submitted by labelers; FDA notes that inclusion does not mean the information was verified or that a product is approved, covered, or reimbursable.
• HCPCS links are derived from CMS NDC–HCPCS crosswalks, which support ASP-based Part B payment and are not a complete list of billable NDCs.
• Product class (brand, generic, biosimilar) is derived from the FDA marketing category and Purple Book license type, not from a commercial compendium.
• Payment limits are Medicare Part B national limits; they do not reflect payer contracts, OPPS rates, 340B pricing, or acquisition cost.
• Home infusion per diem S-codes are matched by therapy category from the FDA pharmacologic class and route, not from a CMS crosswalk. Payers choose which per diem codes they accept, and the right code can depend on the dosing schedule, infusion method, or daily volume.